Home » Newsletters » BioWorld Science

BioWorld Science

July 6, 2011

View Archived Issues

Preclinical and phase I data show LY-2409021 lowers glucose

Preclinical and clinical phase I and II data reported on antidiabetes agent MK-0893

Scripps Research Institute describes first potent lysophospholipid S1P4 receptor antagonists

GSK discloses new lysophospholipid S1P1 receptor agonists

Chimerix and BARDA reach agreement regarding sole-source contract for smallpox antiviral

Almirall launches Sativex in Germany for treatment of spasticity due to MS

Resverlogix's RVX-297 shows promise in model of multiple sclerosis

Boehringer Ingelheim claims new chemokine CCR2 receptor antagonists

New tachykinin NK3 receptor antagonists designed by Roche

Novel serine/threonine-protein kinase Chk1 inhibitors patented

Lundbeck presents new phosphodiesterase 10A inhibitors

Merck KGaA synthesizes new sphingosine kinase 1 inhibitors

Amgen and UCB join with NASA to test sclerostin-targeted antibody onboard space shuttle Atlantis

GSK receives approvals in Japan for Rotarix and Lamictal

Scancell's SCIB-2 cancer vaccine shows encouraging preclinical results

Sorrento Therapeutics is granted second phase I NIAID grant for MRSA program

Urigen and FDA set next steps for URG-101 study in interstitial cystitis

Chugai receives Japanese approval for additional indication of Pegasys/Copegus combination

Once-monthly minodronic acid formulation approved in Japan

BioLineRx enrolls first subject in phase I BL-1021 trial for neuropathic pain

FDA grants orphan drug status to INNO-206 in soft tissue sarcomas

FDA approves Archimedes Pharma's Lazanda for breakthrough cancer pain

Rib-X Pharmaceuticals and Sanofi enter collaboration to develop new classes of antibiotics

Nuvo Research receives FDA clearance to begin clinical testing of lidocaine spray

RESprotect reacquires North American rights to RP-101